Rhythm Pharmaceuticals (RYTM) Current Assets (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Current Assets data on file, last reported at $430.1 million in Q1 2026.

• On a quarterly basis, Current Assets rose 16.46% year-over-year to $430.1 million in Q1 2026; TTM through Mar 2026 was $430.1 million, a 16.46% increase from a year earlier, with the FY2025 full-year figure at $466.9 million, up 24.78% from the prior year.
• Current Assets for Q1 2026 stood at $430.1 million, down from $466.9 million in the prior quarter.
• Over the last five years, Current Assets for RYTM reached as high as $494.8 million in Q3 2025 and fell as low as $235.8 million in Q1 2024.
• Historically, Current Assets has averaged $346.3 million across 5 years, with a median of $354.2 million in 2022.
• Across the five-year window, Current Assets sank 38.5% in 2022 and jumped 56.64% in 2025, its largest moves.
• Year by year, Current Assets stood at $354.2 million in 2022, then decreased by 12.98% to $308.3 million in 2023, then grew by 21.39% to $374.2 million in 2024, then increased by 24.78% to $466.9 million in 2025, then slipped by 7.89% to $430.1 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $430.1 million in Q1 2026, $466.9 million in Q4 2025, and $494.8 million in Q3 2025.